Postpartum diabetes screening among low income women with gestational diabetes in Missouri 2010–2015

Cynthia J. Herrick1,2*, Matthew R. Keller3, Anne M. Trolard4, Ben P. Cooper5, Margaret A. Olsen3 and Graham A. Colditz2

Abstract

Background: Gestational diabetes increases risk for type 2 diabetes seven-fold, creating a large public health burden in a young population. In the US, there are no large registries for tracking postpartum diabetes screening among women in under-resourced communities who face challenges with access to care after pregnancy. Existing data from Medicaid claims is limited as women often lose this coverage within months of delivery. In this study, we aim to leverage data from electronic health records and administrative claims to better assess postpartum diabetes screening rates among low income women.

Methods: A retrospective population of 1078 women with gestational diabetes who delivered between 1/1/2010 and 10/8/2015 was generated by linking electronic health record data from 21 Missouri Federally Qualified Health Centers (FQHCs) with Medicaid administrative claims. Screening rates for diabetes were calculated within 12 weeks and 1 year of delivery. Initial screening after the first postpartum year was also documented.

Results: Median age in the final population was 28 (IQR 24–33) years with over-representation of black non-Hispanic and urban women. In the final population, 9.7% of women had a recommended diabetes screening test within 12 weeks and 18.9% were screened within 1 year of delivery. An additional 125 women received recommended screening for the first time beyond 1 year postpartum. The percentage of women who had a postpartum visit (83.9%) and any glucose testing (40.6%) in the first year far exceeded the proportion of women with recommended screening tests.

Conclusions: Linking electronic health record and administrative claims data provides a more complete picture of healthcare follow-up among low income women after gestational diabetes. While screening rates are higher than reported with claims data alone, there are opportunities to improve adherence to screening guidelines in this population.

Keywords: Gestational diabetes, Postpartum screening, Care transition, Healthcare access, Medicaid

Introduction

More than half of women with gestational diabetes develop type 2 diabetes, with most cases occurring within 5–10 years of the index pregnancy [1, 2]. Additionally, gestational diabetes prevalence is highest among racial and ethnic minorities and women of lower socioeconomic status [3]. Furthermore, while Asian women are more likely to have gestational diabetes, black and Hispanic women are more likely to progress to type 2 diabetes [4]. Following gestational diabetes, both the American Diabetes Association (ADA) and the American Congress of Obstetricians and Gynecologists (ACOG) recommend screening for type 2 diabetes at 4–12 weeks postpartum with a fasting plasma glucose (FPG) or 2 h oral glucose tolerance test (oGTT) and
screening with either of these tests or a hemoglobin A1C (HbA1C) every 1–3 years thereafter [5, 6].

Existing data on screening rates among low income women are limited. A study of 6239 women utilizing South Carolina Medicaid claims data suggested that screening with a recommended test (FPG or oGTT) occurred in only 3.2% of cases between 5 and 13 weeks postpartum [7]. Another claims data study including 2367 women on Medicaid in Maryland found screening with any glucose test occurred in 5.7% of women by 12 weeks and 15.2% by 1 year [8]. These studies likely underestimate screening in this population, given variable Medicaid income eligibility criteria before, during, and after pregnancy. In Missouri, many women become eligible for Medicaid during pregnancy but lose comprehensive coverage 60 days after delivery. In fact, most existing data in the US on screening for type 2 diabetes after a pregnancy with gestational diabetes come from large integrated health systems, single centers, and claims data [7–14]. Fragmentation of care between health systems prevents follow-up of screening over time. Additionally, women receive prenatal and postpartum care in clinics and often deliver in hospitals. Assessing screening time frames post-delivery is difficult if inpatient and outpatient systems are not integrated. Moreover, there are no published data on screening for type 2 diabetes that occurs beyond the first postpartum year.

To better understand healthcare utilization and screening among low income women, addressing a critical gap in the literature, we sought to leverage the strengths of electronic health record (EHR) data and Medicaid claims data to create a unique linked dataset with information on prenatal care through delivery into the postpartum period. We did not limit our data collection to only the first postpartum year, and we incorporated variables describing the neighborhood food and built environment that could have relevance to diabetes screening and prevention. In this manuscript, we describe our procedure for creating this novel data resource and report population estimates for postpartum screening according to guideline recommendations.

**Methods**

Data from most Federally Qualified Health Centers (FQHC) in Missouri flow into a central data repository. Health centers that are members of the Missouri Primary Care Association (MPCA) use different EHR systems, thus all data enters a data warehouse, managed by Azara Healthcare, and is mapped to standardize reporting across fields. Our study was reviewed and approved by the Washington University Human Research Protection Office in October 2015. The Data Use Agreement with the MPCA was fully executed in April 2016, defining how the data would be used and specifying precautions for storing and transferring the data securely. Twenty six of 29 health center systems gave permission for their data to be utilized. Data in the final population of women with gestational diabetes came from 21 health center systems.

Figure 1 provides an overview of the inclusion criteria for the population definition procedure. In July 2016, an initial de-identified dataset was transferred from Azara Healthcare to investigators at Washington University. Azara Healthcare generated random number IDs for each patient in this dataset and included any woman with an International Classification of Diseases, Clinical Modifications versions 9 or 10 (ICD-9/10-CM) diagnosis code or Current Procedural Terminology, 4th edition (CPT-4) code related to pregnancy care in her record between January 1, 2010 and December 31, 2015. Files contained age, race, ethnicity, primary language, patient encounters (date, time, provider name and type (if documented), health center, vital signs, height, weight), charges, payer information, medications and supplies, laboratory data, infant birthweight, and delivery date (if available). However, the clinic EHR data was incomplete in regard to delivery date as well as administrative codes for pregnancy comorbidities and delivery complications.

Therefore, we linked EHR data with Medicaid claims to obtain additional data on pregnancy comorbidities and delivery complications and to define an accurate delivery date for assessing postpartum screening time frames and marking the gestational period. First, we defined ‘potential gestational diabetes candidates’ utilizing criteria for abnormal glucose. This was intentionally broad to be most sensitive in identifying all potential individuals with glucose abnormalities who may have had gestational diabetes during pregnancy. Criteria for the gestational diabetes candidate subset (8008 women) are defined in Fig. 1.

We further narrowed the gestational diabetes candidate subset to those with probable gestational diabetes using claims data. The random number IDs for each patient in the gestational diabetes candidate subset were returned to Azara Healthcare. Identifiers on this subset were securely transferred from Azara Healthcare to the Office of Social and Economic Data Analysis (OSEDA) at the University of Missouri (the state contractor for Medicaid data) for linkage with Medicaid claims data for each individual. Claims data included inpatient and outpatient claims with medical eligibility code, place of service code, revenue codes, provider specialty code, National Provider Identifier, provider type code, and dates of service with ICD-9/10-CM diagnosis, ICD-9-CM/ICD-10-Procedural Coding System (PCS) procedure codes, and CPT-4 codes. Data were linked based upon Medicaid identifier or, if Medicaid identifier was not
available, a ‘fuzzy match’ process with name, date of birth, zip code and phone number was used. Once linked, OSEDA stripped all HIPAA identifiers from the data, retaining only the previously generated random number ID, and transferred this linked file to investigators at Washington University. There were 6402 women in this linked dataset (91% of whom were successfully linked via Medicaid identifier). Address was separately transferred to investigators in conjunction with the randomly generated ID for geographic analyses. No clinical information attached to HIPAA identifiers was transferred between entities, minimizing the risk to confidentiality. Figure 2 illustrates the flow of data from different sources.

Medicaid claims were utilized to most accurately define the delivery date as the provider or facility date associated with a CPT-4 or ICD-9/10-CM or PCS code for delivery. In order to identify this date, a hierarchical algorithm was implemented: 1) facility and provider claims with CPT-4 or ICD 9/10 code for delivery during an inpatient admission; 2) CPT-4 or ICD9/10 code for delivery and an additional code for delivery-related diagnosis or procedure; 3) CPT-4 or ICD 9/10 code for delivery and a provider claim for anesthesia/epidural; 4) CPT-4 or ICD9/10 code for delivery and a provider claim for postpartum care following birth; or 5) 3 or more delivery-specific codes (including pathologic examination of the placenta and revenue code for labor room (720–724, 729)). This is the strictest definition for inclusion: ICD-9/10CM code for gestational diabetes in pregnancy (648.8x, O24.4x) or 2 or more abnormal values on 3 h oGTT by Carpenter and Coustan Criteria: Fasting glucose > 5.27 mmol/L, 1 h glucose > 9.99 mmol/L, 2 h glucose > 8.6 mmol/L, 3 h glucose > 7.77 mmol/L. Deliveries after 10/8/2015 were excluded to allow everyone the opportunity for 84 days (12 weeks) post-delivery records.
The conception date was defined as 280 days (40 weeks) prior to the delivery date, based upon the standard gestational period. The time frame between the conception date and delivery date was used to identify gestational diabetes and pregnancy comorbidities and exclude pre-existing diabetes. The time before the conception date was used to identify pre-existing diabetes for exclusion as well. The strictest definition was applied so that a woman was only included in the final population as having probable gestational diabetes if she had an ICD-9/10-CM diagnosis code for gestational diabetes during the period from conception to delivery or a documented laboratory diagnosis by Carpenter and Coustan criteria on a 3 h oral glucose tolerance test during pregnancy ($n = 1078$). These are standard criteria for diagnosis of gestational diabetes if 2 or more of the following conditions are true: fasting glucose $\geq 5.27 \text{ mmol/L}$, 1 h glucose $\geq 9.99 \text{ mmol/L}$, 2 h glucose $\geq 8.60 \text{ mmol/L}$, 3 h glucose $\geq 7.77 \text{ mmol/L}$. Figure 1 further delineates inclusion and exclusion criteria. The first birth per woman coded for gestational diabetes with no evidence of pre-existing diabetes served as the index delivery. As the primary outcome was receipt of recommended screening by 12 weeks postpartum, individuals with deliveries after October 8, 2015 were excluded as they would not have had the full opportunity to achieve the primary outcome.

For the final population, demographic data including age at delivery, race, ethnicity, and preferred language were available from EHR records. Height and weight to
calculate BMI prior to the index delivery were missing on the majority of the population and are not reported. Home address from EHR records was geocoded using ESRI ArcGIS (Redlands, CA). This information was then associated with a census tract and linked to census tract level variables. These variables included modified retail food environment index (mRFEI), Rural Urban Continuum Codes (RUCC), and access to public transportation. The mRFEI is a measure developed by the Centers for Disease Control and Prevention (CDC) in 2011 and calculated as follows: $100 \times \left( \frac{\text{healthy retailers} + \text{healthy retailers}}{\text{unhealthy retailers + healthy retailers}} \right)$ [16]. Higher scores on this scale represent better access to healthy food. This index classified healthy retailers as supermarkets and large grocery stores, fruit and vegetable markets, and warehouse clubs while unhealthy retailers included small grocery stores, convenience stores, and fast food restaurants. The RUCC from 2013 are defined by census tract and are publicly available [17]. Classification ranges from 1 to 9, defining census tracts according to metropolitan, non-metropolitan urban, and rural areas by population. Individuals were considered to live near public transportation if they lived in a city with bus and/or train routes, as determined by their zip code of residence. The driving distance in kilometers from a woman’s home to nearest health center was also calculated.

Pregnancy comorbidities and delivery complications were defined exclusively using Medicaid claims data as this information was incomplete in EHR records. Specific administrative codes were used to identify each comorbidity or complication (see Additional file 1: Table S1). A pregnancy-specific comorbidity index was calculated using a previously validated algorithm [18]. Healthcare utilization metrics including number of prenatal visits to a healthcare facility, prenatal visits to a certified diabetes educator (CDE), and number of postpartum visits to a healthcare facility were calculated utilizing EHR encounters and CPT-4 codes from the Medicaid claims data. Completion of screening tests for diabetes in the postpartum period was recorded by type of test and time frame. These tests were identified utilizing lab names and results from the EHR or CPT-4 codes from Medicaid claims data. Screening rates were defined as a percent of the final population ($n = 1078$) for FPG, oGTT, HbA1C, and any glucose test within 12 weeks of delivery and from 12 weeks to 1 year postpartum. Screening rates for recommended tests (FPG or oGTT within 12 weeks postpartum and FPG, oGTT, HbA1C after 12 weeks postpartum) were also reported. As some women received multiple screening tests, the unique number and percent of women screened within the first postpartum year and at any point after delivery were also described. Among those who had more than 1 year of postpartum data ($n = 672$), the number and percent of women receiving a first screening test more than 1 year after delivery were calculated. All data management procedures and analyses were conducted using SAS Enterprise Guide v. 7.1 (Cary, NC).

Results
The median age at delivery for women in the final gestational diabetes population ($n = 1078$) was 28 (IQR 24–33) years, and 19.6% of the population was advanced maternal age ($\geq 35$ at delivery). Self-reported racial or ethnic minorities comprised over half of the population with 40.6% of women identifying as black non-Hispanic. Preferred language other than English was reported in 17.9% of the population (with an additional 12.3% not reporting a preferred language), reflecting the large immigrant and refugee populations served by some of the health centers. The majority of the population (69.2%) lived in a metropolitan area with a population > one million, with only 13% living in areas with a population under 20,000 people. The median distance from home to the closest health center was 4.7 km (IQR 2.2–10.4), and 69.5% percent of the population lived near public transportation. There were no healthy food retailers according to the mRFEI in the census tract of residence for 18.9% of the population.

In our final population, 72.1% of the women had a comorbidity index of 1 or higher and 15.6% had a comorbidity index of 4 or higher. This pregnancy specific comorbidity index was initially developed in an external cohort of women on Medicaid in pregnancy. In that cohort, less than 50% of the population had a score of 1 or higher and each additional point increased the risk of maternal end organ injury or death within 30 days of delivery by 37% (95% CI 35–39%) [18]. Hence, our population was relatively complicated for a pregnant population. Pre-existing or transient gestational hypertension were among the most common comorbidities, affecting 21% of the population together. Additionally, 10.5% of women had mild or severe pre-eclampsia. One or more codes for depression were present in 21.4% of the population before or after delivery. In regard to delivery complications, 23.9% of women had a Cesarean section in a prior pregnancy and 34.2% of women had a Cesarean section to deliver the index pregnancy. Table 1 summarizes demographics, comorbidities, and pregnancy and delivery complications.

We next address access to care and adherence to screening guidelines. Seventy three percent of women had a visit to a healthcare facility (documented in either the EHR or Medicaid claims files) in the first 12 weeks postpartum, and 83.9% had a visit within the first postpartum year. The median number of prenatal visits documented in either the EHR or Medicaid claims files was 11.5 (IQR 7–16), and the median number of postpartum visits was 3 (IQR 1–5). Visits in both the prenatal and postpartum time frames could have included visits with a nurse, nurse practitioner, physician's assistant, or physician,
Table 1 Demographics, geographic data, and clinical characteristics of low income women with gestational diabetes in Missouri (n = 1078)

| Demographics | Median (IQR) or n(%) |
|--------------|----------------------|
| Age at delivery | 28 (24–33) |
| Advanced maternal age (35 + at delivery) | 211 (19.6) |
| Race/ethnicity |                      |
| White non-Hispanic (or ethnicity unreported) | 338 (31.4) |
| Black non-Hispanic (or ethnicity unreported) | 438 (40.6) |
| Hispanic | 168 (15.6) |
| Asian | 45 (4.2) |
| Other (Native American, Pacific Islander, More than one Race) | 37 (3.4) |
| Missing/Unreported | 52 (4.8) |
| Preferred Language other than English | 193 (17.9) |
| Preferred Language not available | 133 (12.3) |
| Geographic data |                      |
| Residence in county with metropolitan area > one million (n = 1044) | 722 (69.2) |
| Lived near public transportation (n = 1063) | 739 (69.5) |
| Distance from home to nearest health center (km) (n = 1041) | 4.7 (2.2–10.4) |
| Modified retail food environment index (mRFEI) by census tract (n = 1053) | 9.1 (4.8–14.3) |
| Census tract of residence had no healthy food retailers by mRFEI (n = 1053) | 199 (18.9) |
| Selected comorbidities and pregnancy complications |                      |
| Pregnancy specific comorbidity index ≥ 1d | 777 (72.1) |
| Drug abuse | 55 (5.1) |
| Pre-existing depression | 186 (17.3) |
| Postpartum depression without pre-existing depression | 45 (4.2) |
| Asthma | 95 (8.8) |
| Pre-existing hypertension | 153 (14.2) |
| Transient gestational hypertension w/o pre-existing hypertension | 73 (6.8) |
| Mild pre-eclampsia | 63 (5.8) |
| Severe pre-eclampsia/Eclampsia | 50 (4.6) |
| Selected delivery complications |                      |
| C-section (prior pregnancy) | 258 (23.0) |
| C-section (this pregnancy) | 369 (34.2) |
| Induction | 340 (31.5) |
| Cord complication | 140 (13.0) |
| Chorioamnionitis | 112 (10.4) |
| Preterm labor | 80 (7.4) |
| Abnormal forces of labor | 66 (6.1) |

Table 1 Demographics, geographic data, and clinical characteristics of low income women with gestational diabetes in Missouri (n = 1078) (Continued)

| Demographics | Median (IQR) or n(%) |
|--------------|----------------------|
| Malpresentation | 67 (6.2) |
| Obstruction of labor without dystocia | 48 (4.5) |
| Shoulder dystocia | 40 (3.7) |

a Missing geographic data resulted from inability to match to home address to geocode, out of state address listed, or missing clinic information
b Per the CDC, mean mRFEI in Missouri and nationally is 10
c Other comorbidities present in less than 5% of the population: congenital heart disease, congestive heart failure, ischemic heart disease, human immunodeficiency virus (HIV), alcohol abuse, pulmonary hypertension, chronic renal disease, sickle cell disease, systemic lupus erythematosus, cardiac valve disease, multiple gestation
d In the validation cohort for the comorbidity index, developed in a Medicaid population, less than half the population had a score of 1 or higher. Each additional point increase in comorbidity index was associated with a 37% increase (95% CI 1.35–1.39) in maternal end organ injury or death from delivery to 30 days postpartum
e Other delivery complications present in less than 5% of the population: fetopelvic disproportion, postpartum hemorrhage, placenta previa, placental abruption, other delivery infection, hypotension, severe laceration

as documentation of billing provider in both Medicaid and EHR data was incomplete. Ten percent of the population was on an oral hypoglycemic medication during pregnancy and 2.5% of women were on insulin. For the protocol used to identify medication type in EHR data, (see Additional file 3: Table S3). Twelve percent of women received at least one prenatal visit with a certified diabetes educator. Twenty one percent of the population had a subsequent pregnancy during the study period. Median follow-up for the final population until subsequent pregnancy conception date or last visit date in either EHR or Medicaid claim files was 1.2 years (IQR 0.3–2.5). For those with more than 1 year of data (n = 672), median follow-up time until next pregnancy conception date or last visit date was 2.1 years (IQR 1.3–3.3). Table 2 details healthcare utilization in the final gestational diabetes population.

Table 3 depicts screening rates by type of test and time frame. For the primary outcome, 105 women (9.7% of the total population) received a recommended test (FPG or oGTT) to screen for type 2 diabetes by 12 weeks postpartum. By 1 year postpartum, 204 women (18.9% of the total population) had received a recommended test (HbA1C (if done after 12 weeks), FPG, or oGTT). Of the whole population, 329 women (30.5%) received at least one recommended screening test during the study period and before a subsequent pregnancy. After 12 weeks postpartum, the most common recommended screening test was an HbA1C. At all times points, it was more common to have any glucose test completed than it was to have a recommended test. Any glucose test could include a random blood or urine glucose or a glucose on a complete or basic metabolic panel or renal function panel. More than 1 year of follow-up data were
There are some women who were screened both within 12 weeks and between 12 weeks and 1 year postpartum. Includes random blood or urine glucose, complete metabolic panel, basic metabolic panel, renal function panel, and all recommended tests. Recommended = FPG or 2hoGTT in first 12 weeks; FPG, oGTT, or HbA1C after 12 weeks.

FPG = fasting plasma glucose; 2hoGTT = 2 h oral glucose tolerance test; HbA1C = hemoglobin A1C.

Postpartum diabetes screening rates among low income women with gestational diabetes in Missouri

Table 3 Postpartum diabetes screening rates among low income women with gestational diabetes in Missouri (n = 1078)

| Screening Test | FPG a n (%) | 2hoGTT a n (%) | HbA1C a n (%) | Recommended testb n (%) | Any glucose testc n (%) |
|---------------|-------------|----------------|--------------|-------------------------|-------------------------|
| Whole Population (n = 1078) | | | | | |
| Screened 0–12 weeks postpartumd | 39 (3.6) | 78 (7.2) | 49 (4.6) | 105 (9.7) | 293 (27.2) |
| Screened 12 weeks–one year postpartum d | 16 (1.5) | 15 (1.4) | 107 (9.9) | 121 (11.2) | 246 (22.8) |
| Screened by one year postpartum (unique) | 55 (5.1) | 92 (8.5) | 141 (13.1) | 204 (18.9) | 438 (40.6) |
| Screened at any time from delivery to next pregnancy/last follow-up (unique) | 75 (6.9) | 107 (9.9) | 272 (25.2) | 329 (30.5) | 575 (53.3) |
| Women with > one year follow-up data (n = 672) | | | | | |
| 1st screening test done > one year postpartum | 20 (3.0) | 15 (2.2) | 131 (19.5) | 125 (18.6) | 137 (20.4) |

aFPG = fasting plasma glucose; 2hoGTT = 2 h oral glucose tolerance test; HbA1C = hemoglobin A1C
b Recommended = FPG or 2hoGTT in first 12 weeks; FPG, oGTT, or HbA1C after 12 weeks
c Includes random blood or urine glucose, complete metabolic panel, basic metabolic panel, renal function panel, and all recommended tests
d There are some women who were screened both within 12 weeks and between 12 weeks and 1 year postpartum

Discussion

To our knowledge, this is the first time that statewide EHR data from FQHCs has been linked to Medicaid administrative claims data to provide population estimates of follow-up care among women with gestational diabetes covered by Medicaid during pregnancy. This linked dataset allows us to more comprehensively study a population that is understudied because of fragmentation of care and loss of health insurance after pregnancy. During the study period, Medicaid income eligibility in Missouri was 185–200% of the federal poverty level (FPL) during pregnancy and 22–37% of the FPL for parents after pregnancy [19]. Utilizing the FQHC EHR data allowed us to continue to follow these women after they were no longer covered by Medicaid. Likewise, the Medicaid claims data provided comprehensive delivery information that was unavailable in the clinic record. Through leveraging the strengths of each data source, we present a more complete picture of healthcare for these women. Given that all FQHCs have to report some data to the federal government for the Uniform Data Set, it is possible that this analysis could be replicated in other states through the data vendors for their primary care associations.

Our population is representative of women in Missouri receiving care in FQHCs on Medicaid during pregnancy and as free from bias as possible given the study design and data sources. When compared with publicly available on a subset of women (n = 672). In this group, 125 women (18.6% of the subset) completed a first recommended screening test more than 1 year after the index delivery.

Given the possibility of loss of Medicaid coverage after 60 days postpartum, we examined how screening tests were identified in different time frames (CPT codes came from Medicaid claims and laboratory data came from EHR files). In the first 12 weeks postpartum, it was more common for labs to be identified by CPT code than EHR laboratory data. After 12 weeks postpartum, it was more common for tests to be identified with EHR laboratory data than CPT code data. For the CPT codes used to identify visits and screening tests, (see Additional file 2: Table S2).
available information from the Uniform Data Set, for the centers that consented to use of their data, the number of women included in our population from each health center was generally proportional to the number of prenatal patients delivered at each center during the study period. The racial and ethnic composition of our population was comparable to that expected from publicly reported data on the patient populations served at the included health centers.

We demonstrated higher screening rates for women receiving Medicaid during pregnancy than exhibited in analyses that used administrative claims data alone [7, 8]. We found that 9.7% of our population received a recommended screening test by 12 weeks postpartum (8.4% if restricted to 4–12 weeks postpartum), as compared with 3.2% in South Carolina Medicaid claims. Twenty seven percent of our population had any glucose test at 12 weeks and 40.6% had any glucose test by 1 year postpartum, as compared with 5.7 and 15.2% in a Maryland Medicaid claims population. Moreover, 18.9% of our population had received a recommended test by 1 year postpartum, and 30.5% received a recommended screening test at any point after delivery and before a subsequent pregnancy. While this is lower than screening rates reported in privately insured populations and integrated health systems, [10, 20, 21] our population’s ability to receive optimal follow-up care is complicated by challenges with healthcare access, fragmented care delivery, and other social determinants of health.

Our results show that there are clear opportunities for increasing glucose screening in this population. A majority of women had a visit to a healthcare facility in the postpartum period (73% by 12 weeks and 83.9% by 1 year). Even if we assume that many of the women who had a visit received an order for screening that was not completed, the gap between the number of women with a recommended test and the number of women with any glucose test represents a window of opportunity for increasing screening. Twice as many women received any glucose test (22.8%) as received a recommended test (11.2%) between 12 weeks and 1 year postpartum. As women are getting labs completed for other purposes, and the HbA1C is a non-fasting test, it is possible to increase screening through this modality in the time frame after 12 weeks postpartum.

Another strength of our population is the racial and ethnic diversity, with 40.6% black non-Hispanic women. In many other large studies of postpartum screening, black women have traditionally been under-represented as compared to their proportion of the US population and other racial and ethnic groups [10, 12, 21–25]. Our study adds additional screening data to the literature in this group at high risk for progression to type 2 diabetes [4]. Further, our study reports on screening that occurs more than 1 year after delivery, which is unique to the literature. This is important because it appears that women continue to receive screening after 1 year postpartum, even if they have not been previously screened. Women may be more able to prioritize their health after adapting to the demands of childcare in the first year. Some of these later screening tests may occur incidentally when women present for other healthcare needs. Finally, we were able to incorporate geographic data on our population, including distance from home to nearest clinic, neighborhood food environment, and proximity of public transportation. These factors may affect follow-up care, diabetes screening and diabetes prevention but have not been examined in prior literature.

Our study has a number of limitations. First, we were only able to assess completed or billed laboratory tests and did not have data on all ordered tests. If a laboratory test was not mapped in the central data warehouse or not billed to Medicaid, we would not have captured it. However, we were able to capture at least some point of care glucose and HbA1C measures, in addition to traditional labs, in the central data warehouse. Further, while we could capture screening billed to Medicaid from all sites (FQHC and other) while a woman was still receiving Medicaid, screening after Medicaid lapsed was only available through our FQHC sites. However, as our FQHCs provide essential care for uninsured women and our population was initially identified as receiving care in FQHCs, it is a reasonable assumption that the majority of care for our population would continue to occur in this setting.

We also had no data prior to the prenatal record for 36.6% of women. This is not surprising given that preventive care is often foregone among patients with few resources. Additionally, for 119 women who delivered before October 10, 2010, we did not have the opportunity for a full 280 day prenatal care record. Hence, we may have missed comorbidities or prenatal visits in these women. For the 164 women that delivered in 2015, we did not have the opportunity to capture a full postpartum year and may have missed postpartum screening between 12 weeks and 1 year in this subset; however, excluding these women did not affect screening estimates substantially. For prenatal CDE visits, we were only able to document billed visits. If these visits were not billed by the health center or if the health center provided diabetes education with a non-CDE provider, this would not be captured. This is important to note as many health centers are not able to maintain a CDE on staff. While we have identified visits to a healthcare facility in both prenatal and postpartum time frames, it was difficult to differentiate between nurse visits and visits with a doctor, nurse practitioner, or physician’s assistant. We did assess the Medicaid claims files for visits that had
CPT codes that were level 3 or higher (99203-99205 or 99213-99215) as these are less likely to be nurse-only visits. In the prenatal time frame, the median number of level 3 or higher visits was 5 (IQR 2–9). Level 3 or higher visits were very infrequent in the postpartum time period. Given bundled billing for prenatal and postpartum care, this method likely under-counts visits with a provider.

There were three FQHC systems serving predominately rural populations that did not approve release of their data, leading to over-representation of urban areas in our study population. Additionally, if some centers were better at coding gestational diabetes diagnoses and having laboratory data sent to the centralized data warehouse, we were not able to eliminate that potential bias. While we sought to incorporate clinical data where possible, height, weight, and BMI were available on less than half of the women and are not reported. We utilized administrative codes to identify comorbidities and complications as well as some of the laboratory tests completed for screening. This limitation is mitigated by the fact that many of these codes have been validated in prior studies [15, 18, 26–30]. Medication and supply data were available from the EHR, but not in our administrative claims data. We may have missed oral hypoglycemic therapy or insulin that was added to a patient’s regimen if care was transferred from an FQHC to a specialty center during pregnancy. However, published data suggest that 70–85% of women with gestational diabetes can be managed without medication, so our finding of 12.5% of our population on medication during pregnancy may not underestimate medication use substantially [5]. Finally, while our data is only a subset of the Missouri Medicaid population with gestational diabetes during this time frame, there is a depth of information available in this population that is absent from previously published work.

Conclusions

By utilizing EHR data linked to Medicaid claims data, we have documented that screening for type 2 diabetes after a pregnancy with gestational diabetes occurred in our predominately urban population at rates higher than previously reported in Medicaid claims data alone. However, there are opportunities for increasing screening at all time points. Additionally, documentation of screening after the first postpartum year is important as the risk for developing type 2 diabetes is lifelong. Further analysis of this data will examine individual, health system, and societal factors associated with lack of screening to inform interventions that close the gap between current practice and guideline recommended screening.

Additional files

Additional file 1: Table S1. Conditions and associated ICD9/10-CM Diagnosis or procedure codes. (PDF 32 kb)
Additional file 2: Table S2. Procedures, Visits, and Laboratory tests and associated CPT codes. (PDF 14 kb)
Additional file 3: Table S3. Medication names used in identifying types of diabetes prescriptions. (PDF 8 kb)

Abbreviations

ACOG: American Congress of Obstetricians and Gynecologists; ADA: American Diabetes Association; CDC: Centers for Disease Control and Prevention; CDE: Certified diabetes educator; CI: Confidence interval; CPT-4: Current Procedural Terminology, 4th edition; EHR: Electronic health record; FPG: Fasting plasma glucose; FPL: Federal poverty level; FQHC: Federally Qualified Health Center; HbA1C: Hemoglobin A1C; HIV: Human immunodeficiency virus; ICD-10-CM: International Classification of Diseases, Clinical Modifications versions 9 or 10 diagnosis code; ICD-9-PCS: International Classification of Diseases, Clinical Modifications versions 9 or 10 Procedure Coding System; IQR: Interquartile range; MPCA: Missouri Primary Care Association; mRFEI: Modified retail food environment index; OGTT: Oral glucose tolerance test; OSEDA: Office of Social and Economic Data Analysis; RD: Registered dietician; RUC: Rural Urban Continuum Codes

Acknowledgements

Investigators would like to acknowledge Susan Wilson, MBA (former COO), Joe Piete, MPA (CEO) and Sam Joseph, PA (Center for Healthcare Quality Director) and all member health centers of the MPCA for their support in facilitating this study’s implementation. We would like to acknowledge Jeff Brandes, BS and Philip Parker, MBA at Azara Healthcare for their assistance in EHR data extraction. We would like to acknowledge Jill Lucht, MS and Bhawani Mishra at the Office of Social and Economic Data Analysis (OSEDA) at the University of Missouri for linking identifiers transferred from Azara Healthcare to Medicaid administrative claims. Finally, we would like to acknowledge Bethany Johnson-Javois, MSW, Jane Schaer, MBA, and Heidi Miller, MD from the St. Louis Integrated Health Network for helping to foster approval of this work through the Integrated Health Network Community Academic Partnership group. The development of the population described in this manuscript was previously presented as a poster at the Association of Clinical and Translational Sciences Annual Meeting, April 19-21, 2017 and the Endocrine Society Meeting as a poster and science hub presentation in Chicago, IL March 14-17, 2018.

Funding

Research reported in this publication was supported by grant number 1P30DK092950 from the NIDDK, the Washington University Institute for Clinical and Translational Sciences grant UL1TR000448, sub-award KL2TR002450, and Award Number KL2TR002346 from the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health. MAO and MRK are funded by the Center for Administrative Data Research which is supported in part by the Washington University Institute of Clinical and Translational Sciences grant UL1TR000448 from the National Center for Advancing Translational Sciences (NCATS), Grant Number R24 HS19455 through the Agency for Healthcare Research and Quality (AHRQ), and Grant Number KM1CA156708 through the National Cancer Institute (NCI). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funding sources had no role in the study design, data collection, management, analysis, interpretation of the data, or manuscript preparation.

Availability of data and materials

The data that support the findings of this study are available from the Missouri Primary Care Association and the University of Missouri Office of Social and Economic Data Analysis but were used through a Data Use Agreement for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of the Missouri Primary Care Association and the University of Missouri Office of Social and Economic Data Analysis.
Authors' contributions

CJH conceived of the study, identified collaborators, developed data use agreements, designed data requests, oversaw data transfer, provided clinical expertise, worked with MAO and MK in data management to refine the final population, conducted data analysis, and wrote the manuscript. MK conducted all data management activities to refine the final population and developed the healthcare utilization and screening variables. He drafted portions of the methods section and edited the manuscript. AT conducted the geographic information systems analysis and edited the manuscript. BC worked with CJH to develop the study design and data request plan and work with collaborators to develop data use agreements. He provided mentorship in the use of EHR data and edited the manuscript. MAO provided administrative data analysis expertise and oversaw data management and analysis and edited the manuscript. GAC made substantial contributions to study conception and design, data analysis and interpretation, and manuscript revision. CJH takes full responsibility for the content of this manuscript. All authors have read and approved the manuscript and agree to be accountable for their contributions and the accuracy and integrity of the work.

Ethics approval and consent to participate

Our study protocol number 201510005 was reviewed and approved with a partial HIPAA waiver by the Washington University Human Research Protection Office on October 1, 2015 with last continuing review completed on July 3, 2018.

Consent for publication

Not applicable.

Competing interests

MRK, AMT and GAC have no competing interests to report. CJH received an honorarium for speaking at the annual meeting of the MPCA on October 26, 2018. MAO receives grant funding and provides consultation services for Pfizer and Sanofi Pasteur and serves on an Advisory Board for Pfizer. BPC is an employee of Merck and Co and provides consulting services for AstraZeneca, Gilead, Daiichii Sankyo, Amgen and GAC. CJH is an employee of Merck and Co. AT is an employee of Pfizer. EJS receives research support from the Agency for Healthcare Research and Quality and the National Institute on Aging.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details

1Division of Endocrinology, Metabolism and Lipid Research, Department of Medicine, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8127, St. Louis, MO 63110, USA. 2Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, 660 S. Euclid Ave, Campus Box 8100, St. Louis, MO 63110, USA. 3Division of Endocrinology, Metabolism and Lipid Research, Department of Medicine, Washington University School of Medicine, 4523 Clayton Ave, CB 8051, St. Louis, MO 63110, USA. 4Center for Administrative Data Research, Washington University School of Medicine, 660 S. Euclid Ave, Saint Louis Campus, MO 63110, USA. 5Centene Corporation, 7700 Forsyth Blvd, St. Louis, MO 63105, USA.

Received: 22 November 2018 Accepted: 24 January 2019

Published online: 04 February 2019

References

1. Bellamy L, Casas JP, Hingorani AD, Williams D. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet. 2009; 373(9677):1773–9.
2. Kim C, Newton KM, Knopp RH. Gestational diabetes and the incidence of type 2 diabetes: a systematic review. Diabetes Care. 2002;25(10):1862–8.
3. DeSisto CL, Kim SY, Sharma AJ. Prevalence estimates of gestational diabetes mellitus in the United States, pregnancy risk assessment monitoring system (PRAMS), 2007-2010. Prev Chronic Dis. 2014;11:130415.
4. Xiang AH, Li BH, Black MH, Sacks DA, Buchanan TA, Jacobsen SJ, Lawrence JM. Racial and ethnic disparities in diabetes risk after gestational diabetes mellitus. Diabetologia. 2011;54(12):3016–21.
5. American Diabetes A. 13. Management of Diabetes in pregnancy: standards of medical care in Diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S137–43.
6. Committee on Practice B-O. ACOG practice bulletin no. 190: gestational Diabetes mellitus. Obstet Gynecol. 2018;131(2):e49–64.
7. Hale NL, Probst JC, Liu J, Martin AB, Bennett KJ, Glover S. Postpartum screening for diabetes among Medicaid-eligible South Carolina women with gestational diabetes. Women’s Health Issues. 2011;21(2):e163–9.
8. Bennett WL, Chang H-Y, Levine DM, Wang L, Neale O, Werner EF, Clark JM. Utilization of primary and obstetric care after medically complicated pregnancies: an analysis of medical claims data. J Gen Intern Med. 2013;29(4):36–45.
9. Towar A, Chasan-Taber L, Eggelston E, Oken E. Postpartum screening for diabetes among women with a history of gestational diabetes mellitus. Prev Chronic Dis. 2018;15(6):A124.
10. Ferrara A, Peng T, Kim C. Trends in postpartum diabetes screening and subsequent diabetes and impaired fasting glucose among women with histories of gestational diabetes mellitus: a report from the translating research into action for diabetes (TRIAD) study. Diabetes Care. 2009;32(2):269–74.
11. Canson NP, Frank MI, Keeley E. Original research: postpartum testing rates among women with a history of gestational diabetes - systematic review. Prim Care Diabetes. 2013;7(3):177–86.
12. Morton Eggelston E, LeCates RF, Fang Z, Wharam JF, Ross-Degnan D, Oken E, Eggelston EM, Zhang F. Variation in postpartum glycemic screening in women with a history of gestational Diabetes mellitus. Obstet Gynecol. 2016;128(1):159–67.
13. Battarbee AN, Yee LM. Barriers to postpartum follow-up and glucose tolerance testing in women with gestational Diabetes mellitus. Am J Perinatol. 2018;35(9):854–60.
14. Rosenbloom JL, Blanchard MH. Compliance with postpartum Diabetes screening recommendations for patients with gestational Diabetes. J Women’s Health (Larchmt). 2018;27(4):498–502.
15. Kulikova EV, Whiteman MK, Hills SD, Jamieson DJ, Meikle SF, Posner SF, Marchbanks PA. An enhanced method for identifying obstetric deliveries: implications for estimating maternal morbidity. Matern Child Health J. 2008;12:469–77.
16. Census tract level state maps of the modified retail food environment index (mRFEI) and data tables. ftp://ftp.cdc.gov/pub/Publications/dnpao/census-tract-level-state-maps-mrfei_TAG508.pdf.
17. Rural-Urban Continuum Codes [https://www.ers.usda.gov/data-products/rural-urban-contiuum-codes/].
18. Bateman BT, Mhyre JM, Hernandez-Diaz S, Huybrechts KF, Fischer MA, Creanga AA, Callaghan WM, Gagne JJ. Development of a comorbidity index for use in obstetric patients. Obstet Gynecol. 2013;121(S5):957–65.
19. Kaiser Family Foundation. Trends in Medicaid Income Eligibility [http://kff. org/data-collection/trends-in-medicaid-income-eligibility-limits/].
20. Kim C, Tabaei BP, Burke R, McEwen LN, Lash RW, Johnson SL, Schwartz KL, Bernstein SJ, Herman WH. Missed opportunities for type 2 diabetes mellitus screening among women with a history of gestational diabetes mellitus. Am J Public Health. 2006;96(9):1643–8.
21. Lawrence JM, Black MH, Hsu JW, Chen W, Sacks DA. Prevalence and timing of postpartum glucose testing and sustained glucose dysregulation after gestational diabetes mellitus. Diabetes Care. 2010;33(6):569–76.
22. Blatt AJ, Nakamoto JM, Kaufman HW. Gaps in diabetes screening during pregnancy and postpartum. Obstet Gynecol. 2011;117(1):61.
23. Detz PM, Vesco KK, Callaghan WM, Bachman DJ, Bruce FC, Berg CJ, England LJ, Hornbrook MC. Postpartum screening for diabetes after a gestational diabetes mellitus-affected pregnancy. Obstet Gynecol. 2008;112(4):868–74.
24. Szaekenko M, Cheng YW, McLean T, Jelin AC, Rand L, Caughey AB. Postpartum follow-up for women with gestational diabetes mellitus. Am J Perinatol. 2010;27(7):337–42.
25. Szaekenko M, Liddell J, Cheng YW, Sparks TN, Killorn M, Caughey AB. Patient counseling increases postpartum follow-up in women with gestational diabetes mellitus. Am J Obstet Gynecol. 2011;204(6):S22.e521–6.
26. Metcalfe A, Lix LM, Johnson JA, Currie G, Lyon AW, Herrick ES. Validation of an obstetric comorbidity index in an external population. BJOG. 2015;122(3):658–65.
27. Borrmano KV, Gross GA, Willers DM, Fraser VI, Olsen MA. The effect of clinical chorionicamnionitis on cesarean delivery in the United States. Health Serv Res. 2016.
28. Goff SL, Pekow PS, Markenson G, Knee A, Chasan-Taber L, Lindenaunk PK. Validity of using ICD-9-CM codes to identify selected categories of obstetric complications, procedures and co-morbidities. Paediatr Perinat Epidemiol. 2012;26(5):421–9.
29. Bowker SL, Savu A, Lam NK, Johnson A, Kaul P. Validation of administrative data case definitions for gestational diabetes mellitus. Diabet Med. 2015.

30. Andrade SE, Moore Siñas TA, Boudreau D, Raebel MA, Toh S, Syat B, Dashevsky I, Platt R. Validation of algorithms to ascertain clinical conditions and medical procedures used during pregnancy. Pharmacoepidemiol Drug Saf. 2011;20(11):1168–76.